Sanofi SA Sponsored ADR (SNY)

Over the past six months, Sanofi's stock price has experienced fluctuations, declining approximately 19.95% between March 24, 2025, and March 23, 2026. Positive events include regulatory approvals and pipeline progress, a licensing agreement with Kali Therapeutics, strong Q4 and full-year 2025 results, and a proposed dividend increase. Negative events and pressures include institutional selling and analyst downgrades, broader market headwinds, and slowing earnings growth.

Historically, Sanofi's stock has shown some demand seasonality. December tends to be the strongest month, while January has historically been the weakest. Sanofi has an average annual return of 2.06% with an overall monthly win rate of 55.1%. The seasonal pattern for Sanofi has a consistency score of 42.6 (Poor), suggesting that while patterns exist, they are not always highly reliable. March has shown the highest probability of a positive return.

Sanofi S.A. is a French multinational pharmaceutical and healthcare company focused on researching, developing, manufacturing, and marketing therapeutic solutions, including prescription medicines, vaccines, and consumer healthcare products. It is the world's largest producer of vaccines through its subsidiary, Sanofi Pasteur. Its pharmaceutical products encompass various therapeutic areas, including immunology, oncology, and cardiovascular, while its human vaccines cover pediatric vaccines, flu, and meningitis. The company also has a Consumer Healthcare segment.

Sanofi has a broad global footprint with a significant presence in Europe, North America, and emerging markets. At the end of 2025, the group had 37 production sites worldwide. Its net sales are geographically distributed as follows: the United States (50.8%), Europe (17.1%, with France at 3.9%), China (6%), and other regions (22.2%). Sanofi is present in approximately 100 countries.

Sanofi demonstrates a commitment to sustainability and environmental responsibility, focusing on optimizing waste, managing water, and preserving biodiversity. The company has set ambitious goals, including achieving net-zero greenhouse gas emissions by 2045. Sanofi has been recognized by the CDP for its commitment and transparency on climate change for five consecutive years. The company assesses its biodiversity impacts and is committed to deforestation-free sourcing for key raw materials. No major negative events significantly impacted Sanofi's brand reputation in the past year.

Sanofi's shareholder base includes large asset managers, retirement systems, and hedge funds. As of December 2025, 694 institutional investors held a position in Sanofi. Major institutional owners include Dodge & Cox, Fisher Asset Management, Morgan Stanley, Bank of America Corp, Barrow Hanley Mewhinney & Strauss LLC, BlackRock, Inc., Franklin Resources Inc, Mondrian Investment Partners LTD, Capital World Investors and Invesco Advisers. L'Oréal SA also holds a significant stake.